Objective. —To determine the ability of various antihypertensive agents to reduce left
ventricular hypertrophy, a strong, blood pressure—independent cardiovascular risk factor, in …

… ive and thorough literature search we had missed two randomized double-blind studies in
our first metaThe characteristics of the four antihypertensive drug classes are given in Table 2. …

… history of the hypertension disease process … double-blind, crossover trial comparing the
effects of nebivolol and atenolol on vascular NO bioactivity in patients with essential hypertension…

… Despite this late20th-century research focus on cardiac … treatment of mild, essential
hypertension in patients with otherwise … for the development of primary hypertension. These …

BACKGROUND:: Patients with hypertension may require combination therapy to attain the
blood pressure targets recommended by US and European treatment guidelines. …

… This study was a double-blind, randomized, controlled clinical trial with an 8 … , was studied
as an adjunctive to conventional pharmaceutical therapy. In this study, randomization and blind…

… , double-blind, placebo-controlled studies that randomized 202 and 192 patients with pulmonary
arterial hypertension… The primary end point for each study was change in 6-minute walk …

… This was a phase III, randomized, double-blind, parallel-group study comparing the efficacy
… ) in Japanese patients with grade I or II essential hypertension. In addition, the persistence of …

… D supplementation on primary hypertension. This double-blind randomized clinical trial
was conducted on patients aged 26-84 years with essential hypertension from March 2017 to …

… We performed the first double-blind, randomized trial with LCI699 in patients with primary
hypertension. We randomized 524 patients to LCI699 0.25 mg once daily (n=92), 0.5 mg once …